H1 2005 report from Novo Nordisk shows 25% increase in net profits  

2005.08.12
Healthcare company Novo Nordisk's newly published H1 2005 report shows a net profit of DKK 2.9 bn (USD 493 mn), a 25% increase compared to the same period last year

Healthcare company Novo Nordisk's newly published H1 2005 report shows a net profit of DKK 2.9 bn (USD 493 mn), up 25% on the same period last year. Sales grew by 14% to DKK 15.5 bn (USD 2.6 bn). The results exceeded market expectations. Novo Nordisk has raised its forecast for operating profit growth for the whole of 2005 from 5% to 10%.

Sales growth was generated from both diabetes and biopharmaceutical products, primarily driven by insulin analogues and NovoSeven. Lars Rebien Sørensen, president and CEO of Novo Nordisk was pleased with the results, and said that progress on the US market has strengthened the company's belief in its future growth potential. The news is reported by financial daily newspaper Børsen.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest product portfolio in the industry, including advanced products in the area of insulin delivery systems. It also has a leading position in areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk is headquartered in Bagsværd, north of Copenhagen, and employs 20,250 people in 78 countries.

Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×